Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
The webcast will cover topline findings from the Phase 2 SANRECO trial of divesiran in polycythemia vera, a rare blood disorder.
- Silence Therapeutics held a conference call and webcast on Monday, August 10, 2026, to discuss topline results from the Phase 2 SANRECO trial of its investigational therapy.
- The global clinical-stage biotechnology company leverages its proprietary GOLD platform to create innovative siRNA therapies targeting genes that cause rare and common diseases with high unmet needs.
- Chairman and Interim Principal Executive Officer Iain Ross provided opening remarks, while Steve Romano reviewed the SANRECO study results; Chief Financial Officer Rhonda Helmes and VP Gem Hopkins addressed investor questions.
- Interested parties can access the presentation and press release on the corporate website at silence-therapeutics.com/events, with a webcast replay available in the Investors section.
- Management noted that remarks regarding clinical development plans and future expectations constitute forward-looking statements protected under the Private Securities Litigation Reform Act of 1995.
16 Articles
16 Articles
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a quarterly dosing regimen into Phase III.
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera August 10, 2026 8:00 AM EDTCompany...
Silence Therapeutics Advances Divesiran After Positive Phase 2 Results in Polycythemia Vera
As reported on Fierce Biotech, Silence Therapeutics reported positive phase 2 findings for divesiran, an investigational small interfering RNA (siRNA) treatment for polycythemia vera (PV), a rare blood cancer marked by overproduction of red blood cells. The company plans to begin a phase 3 program in the first half of next year. Divesiran is designed […]
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium